| OMB APPROVAL | ||||
| OMB Number: | 3235-0145 | |||
| Expires: | December 31, 2005 | |||
| Estimated average burden hours per response |
11 | |||
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)*
Introgen Therapeutics, Inc.
Common Stock, $0.001 par value
46119F 10 7
December 31, 2004
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| o | Rule 13d-1(b) | |
| o | Rule 13d-1(c) | |
| þ | Rule 13d-1(d) |
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
SEC 1745 (12-02)
| CUSIP No. 46119F 10 7 | 13 G | Page 2 of 4 Pages | ||
| 1. | Names of Reporting
Persons. I.R.S. Identification Nos. of above persons (entities only). David G. Nance |
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions) |
(a) o
(b) o
| 3. | SEC Use Only |
| 4. | Citizenship or Place of
Organization United States citizen |
| 5. | Sole Voting Power |
|||
| 3,043,945 |
||||
| Number of | 6. | Shared Voting Power |
||
| Shares | ||||
| Beneficially | 0
|
|||
| Owned by Each | 7. | Sole Dispositive Power |
||
| Reporting | ||||
| Person | 3,043,945
|
|||
| With: | 8. | Shared Dispositive Power |
||
|
|
0
|
|||
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person 3,043,945 |
|||
|
|
||||
| 10. | Check if the Aggregate Amount
in Row (9) Excludes
Certain Shares (See Instructions) |
|||
|
|
||||
| 11. | Percent of Class Represented
by Amount In Row (9) 9.7% |
|||
|
|
||||
| 12. | Type of Reporting Person (See
Instructions) IN |
|||
|
|
||||
| Schedule 13G | Page 3 of 4 |
Item 1.
(a) Introgen Therapeutics, Inc., a Delaware corporation
(b) 301 Congress Ave., Suite 1850, Austin, TX 78701
Item 2.
(a) David G. Nance
(b) 301 Congress Ave., Suite 1850, Austin, TX 78701
(c) USA
(d) Common Stock, par value $0.001 per share
(e) 46119F 10 7
Item 3. Not Applicable
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owed: 3,043,945
(b) Percent of class: 9.7%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote 3,043,945
(ii) Shared power to vote or to direct the vote 0
(iii) Sole power to dispose or to direct the disposition of 3,043,945
(iv) Shared power to dispose or to direct the disposition of 0
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Reporting Person has the right to receive and the power to direct the receipt of dividends from or the proceeds from the sale of 2,215,605 shares by virtue of his position as the Chief Executive Officer of Domecq Technologies, Developtech Resources Corporation and Debouchement, Ltd. Mr. Nance holds the right to vote for each entity and has dispositive control over the shares.
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company |
Not Applicable
Item 8. Identification and Classification of Members of the Group
Not Applicable
Item 9. Notice of Dissolution of Group
Not Applicable
| Schedule 13G | Page 4 of 4 |
Item 10. Certification
(a) Not applicable.
(b) Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| February 14, 2005 | ||
| Date | ||
| /s/ David G. Nance | ||
| Signature | ||
| David G. Nance | ||
| Name/Title |
Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)